Rallybio Announces Positive Preliminary Results for RLYB212 anti-HPA-1a Monoclonal Antibody

 -- Preliminary data from the ongoing Phase 1b study shows RLYB212 rapidly and completely eliminates transfused HPA-1a positive platelets --

-- Proof-of-Concept Data Expected in 1Q 2023 --

 

Rallybio Corporation (Nasdaq: RLYB) today announced positive preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

These data demonstrate that one week after a single subcutaneous dose, RLYB212 was able to eliminate transfused HPA-1a positive platelets rapidly compared to placebo in a challenge model of a catastrophic fetal maternal hemorrhage. Additional pharmacokinetic data suggests the opportunity for less frequent dosing.

https://www.biospace.com/article/releases/rallybio-announces-positive-preliminary-results-for-rlyb212-an-anti-hpa-1a-monoclonal-antibody-for-the-prevention-of-fetal-and-neonatal-alloimmune-thrombocytopenia/